Você procurou por: gefitinib (Dinamarquês - Inglês)

gefitinib
gefitinib

aktivt stof: gefitinib.
the active substance is gefitinib.

n patienter gefitinib v.
n patients gefitinib v.

iressa 250 mg tabletter gefitinib
iressa 250 mg tablets gefitinib

gefitinib udviste ikke genotoksisk potentiale.
gefitinib showed no genotoxic potential.

iressa 250 mg filmovertrukne tabletter gefitinib
iressa 250 mg film-coated tablets gefitinib

aktive substanser, hvis plasmakoncentration kan ændres gefitinib
active substances that may have their plasma concentrations altered by gefitinib

det vides ikke, om gefitinib udskilles i modermælk.
it is not known whether gefitinib is secreted in human milk.

hazard ratio (gefitinib versusdocetaxel) og 95% ci
hazard ratio (gefitinib versus docetaxel) and 95% ci

det aktive stof i iressa, gefitinib, er en proteintyrosinkinasehæmmer.
the active substance in iressa, gefitinib, is a protein tyrosine kinase inhibitor.

iressa er et lægemiddel, der indeholder det aktive stof gefitinib.
iressa is a medicine that contains the active substance gefitinib.

der er ingen data for anvendelse af gefitinib hos gravide kvinder.
there are no data from the use of gefitinib in pregnant women.

der er ingen specifik behandling i tilfælde af overdosering af gefitinib.
there is no specific treatment in the event of overdose of gefitinib.

gastrointestinal perforation er blevet rapporteret hos patienter, der tager gefitinib.
gastrointestinal perforation has been reported in patients taking gefitinib.

gefitinib bør anvendes med forsigtighed ved lette til moderate ændringer i leverfunktionen.
gefitinib should be used cautiously in the presence of mild to moderate changes in liver function.

in vitro-data indikerer, at gefitinib er et substrat for membrantransportproteinet pgp.
in vitro data indicate that gefitinib is a substrate for the membrane transport protein pgp.

det er ikke relevant at bruge gefitinib på indikationen nsclc i den pædiatriske population.
there is no relevant use of gefitinib in the paediatric population in the indication of nsclc.

gefitinib hæmmer transportproteinet bcrp in vitro, men den kliniske relevans heraf er ukendt.
gefitinib inhibits the transporter protein bcrp in vitro, but the clinical relevance of this finding is unknown.

den kliniske erfaring har ikke vist en kausal sammenhæng mellem qt-forlængelse og gefitinib.
clinical experience has not shown a causal association between qt prolongation and gefitinib.

eksponeringsforøgelsen kan være klinisk relevant, da uønskede hændelser er relaterede til dosis og eksponering af gefitinib.
this increase in exposure may be of clinical relevance since adverse experiences are related to dose and exposure to gefitinib.